Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23017054 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2637391 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL22403747 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2637867 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2637389 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL19909628 | 0.96 | CNR1 (0.52) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15543930 | 0.96 | CNR1 (0.52) | ALDH1A1CNR1CNR2 | |
| SCHEMBL21235537 | 0.96 | CNR1 (0.52) | ALDH1A1CNR1CNR2 | |
| SCHEMBL12187878 | 0.96 | CNR1 (0.52) | ALDH1A1CNR1CNR2 | |
| SCHEMBL25359611 | 0.96 | CNR1 (0.52) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 602 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577520-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| EP-4262883-B1 | PEG LIPIDS AND LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2025-05-28 | — | — | EP | claimed |
| WO-2025024500-A1 | METHODS AND SYSTEMS FOR TRANSDERMAL IMMUNOTHERAPY | Passport Technologies, Inc. (US) | 2025-01-30 | — | — | WO | claimed |
| US-20240148663-A1 | PEG LIPIDS AND LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2024-05-09 | — | — | US | claimed |
| WO-2024044728-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-02-29 | — | — | WO | claimed |
| EP-4262883-A1 | PEG LIPIDS AND LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2023-10-25 | — | — | EP | claimed |
| WO-2022133344-A1 | PEG LIPIDS AND LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (US) | 2022-06-23 | — | — | WO | claimed |
| EP-3201338-B1 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS B VIRUS GENE EXPRESSION | ARBUTUS BIOPHARMA CORP (CA) | 2021-11-03 | — | — | EP | claimed |
| US-20210284733-A1 | ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-09-16 | — | — | US | claimed |
| US-20200385721-A1 | DELIVERING CRISPR THERAPEUTICS WITH LIPID NANOPARTICLES | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-12-10 | — | — | US | claimed |
| US-9765333-B2 | Compositions and methods for silencing marburg virus gene expression | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-09-19 | — | — | US | claimed |
| EP-3201338-A1 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS B VIRUS GENE EXPRESSION | Protiva Biotherapeutics, Inc. (CA) | 2017-08-09 | — | — | EP | claimed |
| WO-2016197133-A1 | DELIVERING CRISPR THERAPEUTICS WITH LIPID NANOPARTICLES | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2016-12-08 | — | — | WO | claimed |
| EP-3033325-A1 | COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA | Protiva Biotherapeutics, Inc. (CA) | 2016-06-22 | — | — | EP | claimed |
| US-20160151284-A1 | COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2016-06-02 | — | — | US | claimed |
| WO-2016054421-A1 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS B VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC (CA) | 2016-04-07 | — | — | WO | claimed |
| US-20160076035-A1 | COMPOSITIONS AND METHODS FOR SILENCING MARBURG VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2016-03-17 | — | — | US | claimed |
| WO-2015011633-A1 | COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2015-01-29 | — | — | WO | claimed |
| EP-2506879-A1 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS | Protiva Biotherapeutics Inc. (CA) | 2012-10-10 | — | — | EP | claimed |
| WO-2011066651-A1 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-06-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284733-A1 | ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B | CD274, PDCD1, HAVCR2 | ALDH1A1 260/4885CNR1 3309/4885CNR2 4382/4885 |
| US-20160151284-A1 | COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA | NSUN3, CETP, SYNCRIP | ALDH1A1 4595/4885CNR1 3096/4885CNR2 3579/4885 |
| US-20240148663-A1 | PEG LIPIDS AND LIPID NANOPARTICLES | NPC1L1, LDLR, NPC1 | ALDH1A1 2887/4885CNR1 2406/4885CNR2 4195/4885 |
| US-20160076035-A1 | COMPOSITIONS AND METHODS FOR SILENCING MARBURG VIRUS GENE EXPRESSION | PLIN3, PLIN1, PLIN5 | ALDH1A1 3280/4885CNR1 4121/4885CNR2 4502/4885 |
| US-20200385721-A1 | DELIVERING CRISPR THERAPEUTICS WITH LIPID NANOPARTICLES | LDLR, SREBF2, NPC1 | ALDH1A1 1652/4885CNR1 3258/4885CNR2 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.